LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== Adverse effects == Although generally well tolerated and numerous advantages over other antidepressants, SSRIs are not devoid of adverse effects. The adverse effects of SSRIs are usually predictable from a knowledge of their pharmacology and are dose related. Such adverse effects are gastrointestinal dysfunction (nausea, diarrhea, epigastric discomfort), effects on the central nervous system (CNS) (anxiety, fatigue, tremor), anticholinergic effects (dry mouth, blurred vision, drowsiness, difficulty in urination) and sexual dysfunction (anorgasmia, low to no libido, erectile dysfunction, numb genitals, retrograde ejaculation, loss of erotic dreams or delayed ejaculation). Occasionally symptoms of sexual dysfunction persist after discontinuation of SSRIs. SSRIs adverse effects are generally mild and temporary and are more of a discomfort than a serious threat in terms of systemic toxicity. Therefore, the adverse effect profile of the SSRIs may offer certain therapeutic advantages in the management of depression.
== History == Vaccine storage was first developed in the early 1960s, when the infectious smallpox disease outbreaks. During this time, vaccine technology was available and offered for protection. Since smallpox has been one of the deadliest diseases known, the World Health Organization (WHO) prepared to launch a campaign to spread the vaccines and end smallpox in 1966. It was not until 1974 where WHO first introduced the Expanded Programme on Immunization (EPI). The main goal was to make immunization available to every child worldwide by 1990. Immunization of six illnesses was being transported, including tuberculosis, diphtheria, pertussis, tetanus, measles, and polio. Dr. Rafe Henderson, the first director of EPI, designed a plan to deliver temperature-sensitive vaccines across dozens of countries safely. It was an important step to ensure that the vaccines were maintained in their determined conditions and guides towards the development of the cold chain. The WHO supported countries worldwide to ensure the vaccine cold chain is maintained. The cold chain has been implemented for years. After EPI was initiated, over 700,000 measles deaths were prevented, and millions of the target diseases have been prevented. There has been a huge milestone in the vaccine industry as scientists create more vaccines for new types of diseases. Therefore, it has a direct impact on the cost of transportation and different kinds of refrigerator storage either at +2° to +8 °C or +20° to +25 °C.
=== Migration of can components === In canning toxicology, migration is the movement of substances from the can itself into the contents. One toxic substance that can migrate is lead, which causes lead poisoning, but has been phased out of usage in cans since the 20th century. A newer concern is bisphenol A (BPA), a potential endocrine disruptor that is an ingredient in the epoxy commonly used to coat the inner surface of cans. Some cans are manufactured with a BPA-free enamel lining produced from plant oils and resins. In February 2018, the Can Manufacturers Institute, a trade association in the United States, surveyed the industry and reported that at least 90% of food cans no longer contained BPA.
===== MeSH D08.811.277.450 – glycoside hydrolases ===== MeSH D08.811.277.450.066 – amylases MeSH D08.811.277.450.066.050 – alpha-amylase MeSH D08.811.277.450.066.100 – beta-amylase MeSH D08.811.277.450.114 – beta-fructofuranosidase MeSH D08.811.277.450.207 – chitinase MeSH D08.811.277.450.283 – dextranase MeSH D08.811.277.450.329 – disaccharidases MeSH D08.811.277.450.329.738 – sucrase MeSH D08.811.277.450.329.738.700 – sucrase-isomaltase complex MeSH D08.811.277.450.329.865 – trehalase MeSH D08.811.277.450.400 – alpha-L-fucosidase MeSH D08.811.277.450.410 – galactosidases MeSH D08.811.277.450.410.050 – alpha-galactosidase MeSH D08.811.277.450.410.100 – beta-galactosidase MeSH D08.811.277.450.410.100.500 – lactase MeSH D08.811.277.450.410.150 – ceramide trihexosidase MeSH D08.811.277.450.410.400 – galactosylceramidase MeSH D08.811.277.450.420 – glucosidases MeSH D08.811.277.450.420.050 – alpha-glucosidases MeSH D08.811.277.450.420.200 – cellulases MeSH D08.811.277.450.420.200.100 – beta-glucosidase MeSH D08.811.277.450.420.200.200 – cellulase MeSH D08.811.277.450.420.200.400 – cellulose 1,4-beta-cellobiosidase MeSH D08.811.277.450.420.200.450 – endo-1,3(4)-beta-glucanase MeSH D08.811.277.450.420.200.500 – glucan 1,3-beta-glucosidase MeSH D08.811.277.450.420.200.550 – glucan 1,4-beta-glucosidase MeSH D08.811.277.450.420.200.600 – glucan endo-1,3-beta-d-glucosidase MeSH D08.811.277.450.420.375 – glucan 1,4-alpha-glucosidase MeSH D08.811.277.450.420.450 – glycogen debranching enzyme system MeSH D08.811.277.450.420.475 – glycosylceramidase MeSH D08.811.277.450.420.475.400 – glucosylceramidase MeSH D08.811.277.450.426 – glucuronidase MeSH D08.811.277.450.483 – hexosaminidases MeSH D08.811.277.450.483.021 – acetylglucosaminidase MeSH D08.811.277.450.483.044 – alpha-N-acetylgalactosaminidase MeSH D08.811.277.450.483.112 – Beta-N-acetylgalactosaminidase MeSH D08.811.277.450.483.180 – Beta-N-acetylhexosaminidase MeSH D08.811.277.450.483.765 – Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase MeSH D08.811.277.450.529 – hyaluronoglucosaminidase MeSH D08.811.277.450.560 – iduronidase MeSH D08.811.277.450.585 – isoamylase MeSH D08.811.277.450.625 – mannosidases MeSH D08.811.277.450.625.500 – alpha-mannosidase MeSH D08.811.277.450.625.750 – beta-mannosidase MeSH D08.811.277.450.642 – muramidase MeSH D08.811.277.450.692 – neuraminidase MeSH D08.811.277.450.737 – n-glycosyl hydrolases MeSH D08.811.277.450.737.099 – dna glycosylases MeSH D08.811.277.450.737.099.500 – DNA-formamidopyrimidine glycosylase MeSH D08.811.277.450.737.099.750 – thymine dna glycosylase MeSH D08.811.277.450.737.400 – nad+ nucleosidase MeSH D08.811.277.450.737.400.060 – adp-ribosyl cyclase MeSH D08.811.277.450.737.400.060.500 – antigens, cd38 MeSH D08.811.277.450.770 – oligo-1,6-glucosidase MeSH D08.811.277.450.770.800 – sucrase-isomaltase complex MeSH D08.811.277.450.800 – polygalacturonase MeSH D08.811.277.450.950 – xylosidases MeSH D08.811.277.450.950.249 – endo-1,4-beta xylanases MeSH D08.811.277.450.950.500 – xylan endo-1,3-beta-xylosidase
Therefore, techniques utilising relaxation measurements of carbon-13 and deuterium have recently been developed, which enables systematic studies of motions of the amino acid side-chains in proteins. A challenging and special case of study regarding dynamics and flexibility of peptides and full-length proteins is represented by disordered structures. Nowadays, it is an accepted concept that proteins can exhibit a more flexible behaviour known as disorder or lack of structure; however, it is possible to describe an ensemble of structures instead of a static picture representing a fully functional state of the protein. Many advances are represented in this field in particular in terms of new pulse sequences, technological improvement, and rigorous training of researchers in the field.
Sources: en.wikipedia.org
=== Appearance === Color: LEDs can emit light of an intended color without using any color filters as traditional lighting methods need. This is more efficient and can lower initial costs. Cool light: In contrast to most light sources, LEDs radiate very little heat in the form of IR that can cause damage to sensitive objects or fabrics. Wasted energy is dispersed as heat through the base of the LED. Color rendition: Most cool-white LEDs have spectra that differ significantly from a black body radiator like the sun or an incandescent light. The spike at 460 nm and dip at 500 nm can make the color of objects appear differently under cool-white LED illumination than sunlight or incandescent sources, due to metamerism, red surfaces being rendered particularly poorly by typical phosphor-based cool-white LEDs. The same is true with green surfaces. The quality of color rendition of an LED is measured by the Color Rendering Index (CRI). Dimming: LEDs can be dimmed either by pulse-width modulation or lowering the forward current. This pulse-width modulation is why LED lights, particularly headlights on cars, when viewed on camera or by some people, seem to flash or flicker. This is a type of stroboscopic effect.
Cristina Alicia Taylor, Philanthropist and Co-Founder, The Taylor Family Foundation. For charitable services to Children and Young People. Judith Weir, , Master of the King's Music. For services to Music
Although CLIA specifies minimum retention periods, it does not explicitly state which entity retains ownership of the specimen during retention and after the retention period. The US currently lacks well-defined federal regulations governing the ownership and use of physical human tissue specimens, their derivatives, and the biological information they contain. The current standing by bioethicists is that patients who have consented to have their diagnostic specimens collected have also abandoned them, and thus have no ownership rights. The Common Rule permits the use of biospecimens that would otherwise be discarded, provided that the donor can not be identified, though utilization of the materials for research may require Institutional review board (IRB) approval. The Association of American Medical Colleges (AAMC) has taken the stance that it "unambiguously rejects the concept that individuals retain any property interest in their excised tissues." Proponents of patient ownership rights advocate that patients must own their samples so that they can make informed decisions about how the tissues will be used, such as in bioweapons development, stem cell research, and for-profit ventures.
== Role in Peptide Synthesis == The use of Fmoc as a temporary protecting group for amine at the N-terminus in solid phase synthesis is very widespread for Fmoc/tBu approach, because its removal with piperidine does not disturb the acid-labile linker between the peptide and the resin. A typical SPPS Fmoc deprotection is performed with a solution of 20% piperidine in N,N-dimethylformamide (DMF).
=== Phagocytosis === Half-maximum stimulation is attained at about 100 nM. Stimulation of phagocytosis is obtained with polymorphonuclear leukocyte (PMN) cells from human, dog, rabbit and cow as well as with macrophages from the lung and peritoneal cavity of mice, guinea pig and mouse bone marrow cells. This effect is inhibited by peptide analogue Thr-Lys-Pro-Pro-Arg. Basal activity is not inhibited, so basal phagocytosis may follow a different pathway from that which follows stimulation. Stimulation of pinocytosis is exerted only on phagocytic cells, not on cultured cell line mouse leukemia.
Sources: en.wikipedia.org
== Strength == Dihydromorphine is slightly stronger than morphine as an analgesic with a similar side effect profile. The relative potency of dihydromorphine is about 1.2 times that of morphine. In comparison, the relative potency of dihydrocodeine is around 1.2 to 1.75 times that of codeine.
Diets to promote weight loss can be divided into four categories: low-fat, low-carbohydrate, low-calorie, and very low calorie. Many dietary patterns are effective. A meta-analysis of six randomized controlled trials found no difference between three of the main diet types (low calorie, low carbohydrate and low fat), with a 2–4 kilograms (4.4–8.8 lb) weight loss in all studies. At two years these three methods resulted in similar weight loss irrespective of the macronutrients emphasized. High protein diets do not appear to make any difference. A diet high in added sugars such as those in soft drinks increases weight. There is evidence that dieting alone can be effective for weight loss and improving health for obese individuals. However, a large study of adults found that obesity was associated with differences in brain structure, largely due to shared genetic factors, suggesting that interventions for obesity should not focus solely on energy content, but also take into account the neurobehavioral profile that obesity is genetically associated with. Dieting for calorie restriction is advised for overweight individuals by the Dietary Guidelines for Americans and United Kingdom's NICE.
1787–1797: Self-taught Chinese astronomer Wang Zhenyi published at least twelve books and multiple articles on astronomy and mathematics. Using a lamp, a mirror and a table, she once created a famous scientific exhibit designed to accurately simulate a lunar eclipse. 1786–1797: German astronomer Caroline Herschel discovered eight new comets, along with numerous other discoveries. 1789: French astronomer Louise du Pierry, the first Parisian woman to become an astronomy professor, taught the first astronomy courses specifically open to female students. 1794: British chemist Elizabeth Fulhame invented the concept of catalysis and published a book on her findings. c. 1796–1820: During the reign of the Jiaqing Emperor, astronomer Huang Lü became the first Chinese woman to work with optics and photographic images. She developed a telescope that could take simple photographic images using photosensitive paper. 1797: English science writer and schoolmistress Margaret Bryan published A Compendious System of Astronomy, including an engraving of herself and her two daughters. She dedicated the book to her students.
On November 25, Karriem was arraigned on charges of first-degree murder; he pleaded guilty, but his bizarre courtroom behavior convinced witnesses of his insanity. Judge John P. Scallen appointed three psychiatrists. Karriem was described as throwing furniture at other prisoners. Papers described Karriem's confinement in a padded cell of the County Jail, writing "The lustful flame of jungle fanaticism which tortured Harris into murdering Smith, seemed to have died away in him, temporarily at least, Saturday [November 26]." On November 28, "Negro leaders" in Detroit publicly voiced opposition to the "cult". By November 29, police had seized ATI literature including a registry of 8,000 members. On November 30, papers reported that Ugan Ali was likely insane, while Fard was reported as "not driven into his sinister teaching through insanity". On December 1, papers announce that the roster of ATI members had been conveyed to the Welfare Departments; Recipients were to be banned from welfare if they retained their membership. On December 6, the three psychiatrists testified that Karriem was legally insane, and he was committed to the Ionia State Hospital for the Criminal Insane. On December 6, Ugan Ali was released after promising to help disband the Allah Temple of Islam, while Fard agreed to forever leave Detroit as a condition of release. In the state hospital, Karriem was diagnosed with dementia praecox. He died there on June 19, 1935, of "mitral insufficiency and decompensation".
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.